|  |  | Thalidomide |
Thalidomide, originally a morning sickness drug in the 1950s, may be used in the treatment of myeloma. Thalidomide disrupts the signalling pathwyas between the myeloma cells and the environment that they live in, causing death of the myeloma. Although thalidomide has shown promising results in clinical trials, many patients find the side effects unacceptable.
| Free full text papers on thalidomide |
 | | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
Haematologica 90(12) 2005 1650-4 |
| Revlimid |
Revlimid (lenolidomide) is one of the next generation of thalidomide-derived drugs called the ‘imids’. These drugs work in a similar way to thalidomide but aim to cause less severe side effects. Relimid is currently in clinical trials in the UK. |
| |
| |
